Filtered By:
Vaccination: Ebola Vaccine
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 607 results found since Jan 2013.
Identification of a dual acting SARS-CoV-2 proteases inhibitor through in silico design and step-by-step biological characterization
Eur J Med Chem. 2021 Sep 22;226:113863. doi: 10.1016/j.ejmech.2021.113863. Online ahead of print.ABSTRACTCOVID-19 pandemic, starting from the latest 2019, and caused by SARS-CoV-2 pathogen, led to the hardest health-socio-economic disaster in the last century. Despite the tremendous scientific efforts, mainly focused on the development of vaccines, identification of potent and efficient anti-SARS-CoV-2 therapeutics still represents an unmet need. Remdesivir, an anti-Ebola drug selected from a repurposing campaign, is the only drug approved, so far, for the treatment of the infection. Nevertheless, WHO in later 2020 has rec...
Source: European Journal of Medicinal Chemistry - September 27, 2021 Category: Chemistry Authors: Veronica Di Sarno Gianluigi Lauro Simona Musella Tania Ciaglia Vincenzo Vestuto Marina Sala Maria Carmina Scala Gerardina Smaldone Francesca Di Matteo Sara Novi Mario Felice Tecce Ornella Moltedo Giuseppe Bifulco Pietro Campiglia Isabel M Gomez-Monterrey Source Type: research
A computational overview on phylogenetic characterization, pathogenic mutations, and drug targets for Ebola virus disease
Curr Opin Pharmacol. 2021 Sep 23;61:28-35. doi: 10.1016/j.coph.2021.08.015. Online ahead of print.ABSTRACTThe World Health Organization declared Ebola virus disease (EVD) as the major outbreak in the 20th century. EVD was first identified in 1976 in South Sudan and the Democratic Republic of the Congo. EVD was transmitted from infected fruit bats to humans via contact with infected animal body fluids. The Ebola virus (EBOV) has a genome size of ∼18,959 bp. It encodes seven distinct proteins: nucleoprotein (NP), glycoprotein (GP), viral proteins VP24, VP30, VP35, matrix protein VP40, and polymerase L is considered a prime...
Source: Current Opinion in Pharmacology - September 26, 2021 Category: Drugs & Pharmacology Authors: Karthick Vasudevan D Thirumal Kumar S Udhaya Kumar Aisha Saleem N Nagasundaram R Siva Iftikhar Aslam Tayubi C George Priya Doss Hatem Zayed Source Type: research
From Drug Design To Distribution: This Is How Robotics, A.I. and Blockchain Transforms Pharma
Exoskeletons to aid pharma factory workers. 3D printing to allow pharmacies to produce drugs on the spot. Blockchain technologies to help fight counterfeit drugs.
These are just bits and pieces, but the entire process of the pharmaceutical supply chain will be affected by disruptive technologies. Let me show you how innovations will make it more efficient, faster and cheaper than ever before.
“We call it Robi”, the smiling pharmacist told me when I looked at the robotic dispenser pacing up and down in a small glass-fronted drug storage room of the pharmacy. The robot spares humans about two hours of med...
Source: The Medical Futurist - September 21, 2021 Category: Information Technology Authors: berci.mesko Tags: 3D Printing Artificial Intelligence in Medicine Augmented Reality Future of Medicine Future of Pharma Robotics Security & Privacy AI digital Innovation Personalized medicine pharmacies blockchain pharmaceutics robots supply c Source Type: blogs
The 2013-2016 Ebola virus disease outbreak in West Africa
This study identified some of the factors that complicated the outbreak, which include delay in the identification of the pathogen, weak health systems, unavailability of licensed drugs or vaccines for the disease, delay in global responses, and cultural practices. Responses were mostly limited to testing, barrier nursing, and treatment of complications. Experimental drugs and vaccines were deployed on compassionate grounds, few have been further developed, trialed, and licensed. It is therefore expected that the current outbreak of Ebola virus disease in Guinea will be better managed.PMID:34537503 | DOI:10.1016/j.coph.2021.08.002
Source: Current Opinion in Pharmacology - September 19, 2021 Category: Drugs & Pharmacology Authors: Elijah Ige Ohimain Daniel Silas-Olu Source Type: research
Third-generation smallpox vaccine strain-based recombinant vaccines for viral hemorrhagic fevers
Vaccine. 2021 Sep 11:S0264-410X(21)01169-5. doi: 10.1016/j.vaccine.2021.09.001. Online ahead of print.ABSTRACTVaccinia virus has been used as a smallpox vaccine. Now that smallpox has been eradicated, the vaccinia virus is expected to be used as a bioterrorism countermeasure and a recombinant vaccine vector for other infectious diseases, such as viral hemorrhagic fevers. Many vaccinia virus strains were used as smallpox vaccines in the smallpox eradication campaign coordinated by the World Health Organization. These strains can be classified into generations, according to the history of improving production methods and eff...
Source: Vaccine - September 15, 2021 Category: Allergy & Immunology Authors: Tomoki Yoshikawa Source Type: research
